Actively Recruiting
Fibroscan to Guide Post Transplant Immunosuppression Minimization
Led by University of Alberta · Updated on 2026-01-08
50
Participants Needed
1
Research Sites
160 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Following Liver transplantation, recipients remain on life long immunosuppression. Prolonged exposure to immunosuppression is associated with side effects and complications including kidney dysfunction, diabetes, heart disease and cancer risk. Therefore studies are looking at safe ways to reduce or stop immunosuppression. An individual without autoimmune liver disease (these patients are at higher risk of rejection), without history of rejection, with normal blood tests (liver biochemistry, liver function, etc.) can be eligible for minimization of immunosuppression. A recent study showed use of fibroscan (an Ultrasound, which provides information on liver stiffness (diseased liver is hard while a normal liver is soft) and fat content) provides more objective information to help investigators select individuals who will tolerate immunosuppression minimization. Our goal is to see if use of fibroscan allows the investigators to safely minimize immunosuppression in eligible individuals. The secondary aims are to assess benefit on kidney function, heart disease and risk factors for heart disease.
CONDITIONS
Official Title
Fibroscan to Guide Post Transplant Immunosuppression Minimization
Who Can Participate
Eligibility Criteria
You may qualify if you...
- At least 2 years have passed since liver transplantation
- Age 18 years or older
You will not qualify if you...
- Diagnosis of acute or chronic rejection within the past 12 months
- Abnormal liver enzymes (ALT > 50) or bilirubin levels (> 19 umol/L)
- Transplant due to autoimmune liver diseases (autoimmune hepatitis, primary sclerosing cholangitis, primary biliary cholangitis)
- Presence of hepatitis C virus RNA
- Presence of hepatitis B virus DNA
- Presence of class II donor specific antibodies (pre-existing or new)
- More than 6 years since transplantation
- Presence of ascites, decompensated heart failure, biliary obstruction
- Chronic kidney disease with estimated glomerular filtration rate 30 ml/min/1.73m2 or less
- History of re-transplantation or multi-visceral transplant
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Alberta
Edmonton, Alberta, Canada, T6G2R3
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here